Revolutionize vaccine development with the AI tool EVEscape. Predict future viral variants for more effective vaccines. Groundbreaking research from Harvard and Oxford.
HilleVax announces $100M public offering to accelerate development of HIL-214 vaccine for norovirus-induced gastroenteritis. Learn more about their mission to improve global health outcomes.
New study suggests exposure to common cold coronaviruses may provide pre-existing immunity to COVID-19. Important implications for vaccine development and pandemic preparedness.
India's first Omicron booster vaccine, GEMCOVAC® -OM, has been launched. Developed by Gennova, with funding support from DBT and BIRAC, this unique mRNA-based vaccine can be administered without an injection and does not require ultra-cold chain infrastructure. It has received Emergency Use Authorization and is a thermostable vaccine that can be deployed to remote locations. With its future-ready technology platform, India is committed to fighting the COVID-19 pandemic.
Revolutionize vaccine development with the AI tool EVEscape. Predict future viral variants for more effective vaccines. Groundbreaking research from Harvard and Oxford.